Bristol-Myers Squibb Commits to SCRS
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to the interests of clinical research sites, announced a two-year partnership with Bristol-Myers Squibb.
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to the interests of clinical research sites, announced a two-year partnership with Bristol-Myers Squibb, a leading global biopharmaceutical company. Bristol-Myers Squibb will participate as a Global Impact Partner (GIP), a relationship indicative of Bristol-Myers Squibb’s dedication to promoting greater site sustainability across the global clinical research landscape. Bristol-Myers Squibb will also host a Site Advocacy Group. As a GIP, Bristol-Myers Squibb will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council in the development and execution of strategic initiatives for SCRS.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
